5-methoxymethyl-2'-deoxyuridine (also known as M(m)dUrd or 5-MOMdUrd) is a synthetic nucleoside analog that is an inhibitor of thymidylate synthase (TS). It is an effective anticancer agent that has been shown to be active against a variety of human cancers, including leukemia, lymphoma, and breast cancer. 5-MOMdUrd is a prodrug that is converted to its active form, 5-methoxymethyl-2'-deoxyuridine 5'-monophosphate (M(m)dUMP), by the enzyme thymidine kinase. M(m)dUMP is a potent inhibitor of TS, which is an essential enzyme for the biosynthesis of thymidine. By inhibiting TS, 5-MOMdUrd prevents the formation of thymine, a key component of DNA. This ultimately leads to the inhibition of DNA synthesis and cell proliferation. 5-MOMdUrd is being studied for its potential as an anticancer agent. It is currently in clinical trials for the treatment of various types of cancer. In addition to its anticancer activity, 5-MOMdUrd has also been shown to have antiviral activity. It is active against a variety of viruses, including herpes simplex virus, varicella-zoster virus, and cytomegalovirus. 5-MOMdUrd is being investigated as a potential treatment for viral infections. Research on 5-MOMdUrd is ongoing to better understand its mechanism of action and to develop new therapeutic applications.'
```
5-methoxymethyl-2'-deoxyuridine: used in treatment of experimental herpes simplex keratitis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 119051 |
SCHEMBL ID | 8191817 |
MeSH ID | M0083247 |
Synonym |
---|
mmdurd |
mmudr |
5-methoxymethyl-2'-deoxyuridine |
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(methoxymethyl)pyrimidine-2,4-dione |
methoxymethyl deoxyuridine |
alpha-methoxythymidine |
thymidine, alpha-methoxy- |
2'-deoxy-5-(methoxymethyl)uridine |
5-methoxymethyldeoxyuridine |
uracil, 1-(2-deoxy-beta-d-erythro-pentofuranosyl)-5-(methoxymethyl)- |
2'-deoxy-5-methoxymethyluridine |
1-(2-deoxy-beta-d-ribofuranosyl)-5-methoxymethyluracil |
uridine, 2'-deoxy-5-methoxymethyl- |
5116-22-3 |
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methoxymethyl)pyrimidine-2,4-dione |
BRD-K68812989-001-01-5 |
SCHEMBL8191817 |
DTXSID00199185 |
1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(methoxymethyl)pyrimidine-2,4(1h,3h)-dione |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 13 (92.86) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.50) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |